mycophenolic acid

mycophenolic acid
IUPAC name	(E)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoic acid
CAS number	24280-93-1
PubChem	446541
DrugBank	DB00688
ChemSpiderID	393912
Molecular formula	C17H20O6
Molar mass	320.34 g/mol
Melting point	141 °C
Boiling point	573.5 °C

mycophenolic acid is an immunosuppressant medication and a secondary metabolite produced by several Penicillium fungi. It is primarily used to prevent organ transplant rejection, often in combination with other agents like ciclosporin and corticosteroids. Its development marked a significant advancement in transplant medicine, offering a more targeted mechanism than earlier cytotoxic drugs.

Chemical properties and structure

Mycophenolic acid is a phenolic acid with a complex structure featuring an isobenzofuran core. The molecule contains a carboxylic acid group and an enol ether functional group, which are critical for its biological activity. Its E-isomer configuration is the biologically active form, and it exhibits limited solubility in aqueous solution but is formulated as the more soluble prodrug mycophenolate mofetil for clinical use. The compound's structure was first fully elucidated through work by Robert Burns Woodward and his team, utilizing techniques like nuclear magnetic resonance spectroscopy.

Medical uses

The primary use of mycophenolic acid is in the prophylaxis of acute rejection following kidney transplant, heart transplant, and liver transplant. It is a cornerstone of maintenance immunosuppression regimens developed by institutions like the Mayo Clinic and Brigham and Women's Hospital. It is also used off-label in the treatment of certain autoimmune diseases, such as lupus nephritis, as investigated in trials like the Aspreva Lupus Management Study. Administration is typically oral, with dosing carefully monitored due to its narrow therapeutic index.

Mechanism of action

Mycophenolic acid acts as a selective, non-competitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis pathway of guanine nucleotides. This inhibition preferentially affects lymphocytes, as these cells are highly dependent on this pathway for proliferation. By depleting intracellular guanosine triphosphate pools, it suppresses T cell and B cell clonal expansion, thereby dampening the immune response. This mechanism was a focus of research at Stanford University and differs from that of calcineurin inhibitors.

Adverse effects

Common adverse effects include gastrointestinal disturbances such as diarrhea, nausea, and vomiting, which often limit dosing. Significant hematological toxicity, including leukopenia and anemia, requires regular monitoring of complete blood counts. There is an increased risk of opportunistic infections, notably cytomegalovirus and BK virus, and a potential elevated risk of lymphoproliferative disorders. The U.S. Food and Drug Administration mandates a black box warning regarding these risks of infection and malignancy.

History and development

Mycophenolic acid was first isolated in 1896 by Gosio Bartolomeo from a Penicillium glaucum culture, but its biological activity remained unexplored for decades. Its immunosuppressive properties were rediscovered in the 1970s by a team at the University of Wisconsin–Madison led by Nelson J. Leonard. The pharmaceutical company Roche later developed the prodrug mycophenolate mofetil, which gained approval from the U.S. Food and Drug Administration in 1995 for kidney transplantation following pivotal clinical trials.

Society and culture

The drug is marketed under brand names including CellCept and Myfortic by Hoffmann-La Roche and Novartis, respectively. Its introduction had a substantial economic impact on transplant medicine and sparked debates over the cost of specialty drugs. The compound has also appeared in popular culture, referenced in medical dramas like *House* and Grey's Anatomy. Its role in enabling successful organ transplant protocols has been recognized by organizations like the American Society of Transplantation.

Category:Immunosuppressants Category:Organ transplantation Category:Antimetabolites